CD8A and melanoma: In a subsequent larger study utilizing the same CD8-targeted PET imaging agent, Farewell et al. evaluated 89Zr-IAB22M2 uptake in 15 patients with melanoma, NSCLC, and HCC, half of whom were undergoing immunotherapy treatment.